FDA approves Novo Nordisk’s liraglutide for reduced risk of major CV events - NASH Pass

About Us
Careers
Client Login
Clinical Research Methods
Automated Glucose Clamp Procedures
Stable Isotope Tracer Methodologies
Advanced Imaging Biomarkers
Circulating and Functional Biomarkers
Glucose, Lipid and Mixed-Meal Tolerance Tests
Indirect Calorimetry
Nutritional Assessments
Tissue Biopsies